ESH EUROPEAN SCHOOL OF HAEMATOLOGY

6th Translational Research Conference
Multiple Myeloma

October 7-9, 2022 - Mandelieu, France

Chairpersons : Maria-Victoria Mateos, Philippe Moreau, Vincent Rajkumar

Friday, October 7th, 2022

08:45–08:55	**Welcome**	Irene Ghobrial (Boston), Graham Jackson (Newcastle), Shaji Kumar (Rochester)

SESSION I – Smoldering myeloma
Chair: Irene Ghobrial (Boston)

08:55-09:00	Introduction	Irene Ghobrial (Boston)
09:00-09:15	Biology of smoldering : a different disease ?	Irene Ghobrial (Boston)
09:15-09:20	*Discussion*	
09:20-09:35	Definition of high-risk SMM in 2022	Maria-Victoria Mateos (Salamanca)
09:35-09:40	*Discussion*	
09:40-09:55	Clinical trials in SMM : past and future	Sagar Lonial (Atlanta)
09:55-10:00	*Discussion*	
10:00-10:30	*Panel discussion*	
10:30-11:00	***Coffee Break***	

SESSION II – Diagnosis of multiple myeloma
Chair: Shaji Kumar (Rochester)

11:00-11:05	Introduction	Shaji Kumar (Rochester)
11:05-11:20	Diagnostic criteria and initial workup	Albert Oriol (Barcelona)
11:20-11:25	*Discussion*	
11:25-11:40	Genetics and risk assessment	Jill Corre (Toulouse)
11:40-11:45	*Discussion*	
11:45-12:00	Imaging at diagnosis in 2022	Evangelos Terpos (Athens)
12:00-12:05	*Discussion*	
12:05-12:35	*Panel discussion*	

12:35-14:40 ***Lunch***

13:25-14:25 **SATELLITE SYMPOSIUM**
Practical management of special clinical situation in Multiple Myeloma
Chair: Philippe Moreau (Nantes)
Speakers: Martin Kortuem (Würzburg), Alessandra Larocca (Turin), Philippe Moreau (Nantes)

This symposium is organised and funded by GSK

SESSION III – Frontline therapy in patients not eligible for autologous stem cell transplantation
Chair: Graham Jackson (Newcastle)

14:40-14:45	Introduction	Graham Jackson (Newcastle)
14:45-15:00	VRD or DRd ?	Vincent Rajkumar (Rochester)
15:00-15:05	*Discussion*	
15:05-15:20	Quadruplet in elderly patients; is it manageable ?	Kwee Yong (London)
15:20-15:25	*Discussion*	
15:25-15:40	How to assess frailty in 2022 ?	Gordon Cook (Leeds)
15:40-15:45	*Discussion*	
15:45-16:15	*Panel discussion*	

16:15-16:45 ***Coffee break***

SESSION IV – Frontline therapy in patients eligible for autologous stem cell transplantation
Chair: Philippe Moreau (Nantes)

16:45-16:50	Introduction	Philippe Moreau (Nantes)
16:50-17:05	Quadruplet induction for all patients ?	Cyrille Touzeau (Nantes)
17:05-17:10	*Discussion*	
17:10-17:25	Maintenance : 2 agents for all ?	Graham Jackson (Newcastle)
17:25-17:30	*Discussion*	
17:30-17:45	Ultra high risk : ASCT + immunotherapy ?	Martin Kaiser (London)
17:45-17:50	*Discussion*	
17:50-18:20	*Panel discussion*	

18:25 **Mentored Poster Walks and Welcome Get Together stand up buffet dinner**

- *Biology Poster Walk Leader : Jill Corre (Toulouse)*
- *Clinical Poster Walk Leaders: Xavier Leleu (Poitiers), Fredrik Schjesvold (Oslo)*

Saturday, October 8th, 2022

09:00-10:00 Simultaneous Meet the Expert sessions

1. How to select ADCs, Bispecifics vs CAR-Ts in the future in the triple class exposed-refractory MM patient? — Xavier Leleu (Poitiers)
2. Management of the toxicity with CAR-Ts and bispecifics mAbs? — Salomon Manier (Lille)
3. Optimal sequencing of treatment in Myeloma in 2022 — Elena Zamagni (Bologna)

10:00-10:30 Coffee break

SESSION V – MRD and the microenvironment
Chair: Hervé Avet-Loiseau (Toulouse)

10:30-10:35	Introduction	Hervé Avet-Loiseau (Toulouse)
10:35-10:50	MRD evauation in the bone marrow	Stefania Oliva (Turin)
10:50-10:55	*Discussion*	
10:55-11:10	MRD evaluation by imaging	Elena Zamagni (Bologna)
11:10-11:15	*Discussion*	
11:15-11:30	MRD evaluation in the peripheral blood	Noemí Puig (Salamanca)
11:30-11:35	*Discussion*	
11:35-12:05	*Panel discussion*	

12:05-13:55 Lunch

12:45-13:45 **SATELLITE SYMPOSIUM**
Translating recent advancements in MM treatment into patients' care
Chair: Salomon Manier (Lille)
Speakers: Salomon Manier (Lille), Roberto Mina (Turin), Rakesh Popat (London)

Satellite Symposium sponsored by Celgene, a Bristol-Myers Squibb Company.

SESSION VI – Relapsed multiple myeloma
Chair: Fredrik Schjesvold (Oslo)

13:55-14:00	Introduction	Fredrik Schjesvold (Oslo)
14:00-14:15	Treatment at biochemical versus clinical relapse	Enrique Ocio (Santander)
14:15-14:20	*Discussion*	
14:20-14:35	How to rescue patients after the SOC in 1st line in 2022?	Saad Usmani (Charlotte)
14:35-14:40	*Discussion*	

14:40-14:55	Current options for 3rd line of therapy	Fredrik Schjesvold (Oslo)
14:55-15:00	*Discussion*	
15:00-15:30	*Panel discussion*	
15:30-16:00	***Coffee break***	

SESSION VII – The future: recent clinical trials in relapse
Chair: Nizar Bahlis (Calgary)

16:00-16:05	Introduction	Nizar Bahlis (Calgary)
16:05-16:20	Where, when and how to use ADC in MM?	Rakesh Popat (London)
16:20-16:25	*Discussion*	
16:25-16:40	Where, when and how to use CAR- cells in MM?	Salomon Manier (Lille)
16:40-16:45	*Discussion*	
16:45-17:00	Where, when and how to use bi-specifics mAbs in MM?	Nizar Bahlis (Calgary)
17:00-17:05	*Discussion*	
17:05-17:45	**DEBATE*:*** Artificial Intelligence in myeloma: reality or fiction	

Audience votes REALITY or FICTION

17:05-17:20	Reality	Adrian Mosquera (Santiago de Compostela)
17:20-17:35	Fiction	Mohamad Mohty (Paris)
17:35-17:45	*Discussion*	

Audience votes REALITY or FICTION

Sunday, October 9th, 2022

07:45-08:45 Simultaneous Breakfast Meet the Expert Sessions

1. Management of high risk myeloma patients — Martin Kaiser (London)
2. MRD evaluation in the clinical practice — Noemi Puig (Salamanca)

SESSION VIII – Clinical trial design and management issues
Chair: Philippe Moreau (Nantes)

08:55-09:00	Introduction	Philippe Moreau (Nantes)
09:00-09:15	Control arms in regulatory trials	Graham Jackson (Newcastle)
09:15-09:20	*Discussion*	

09:20-09:35	Strategic questions for investigator initated trials	Philippe Moreau (Nantes)
09:35-09:40	*Discussion*	
09:40-09:55	Endpoints for frontline therapy	Shaji Kumar (Rochester)
09:55-10:00	*Discussion*	
10:00-10:30	*Panel discussion*	

10:30-11:00 Coffee break

SESSION IX – Plasma cell disorders
Chair: Shaji Kumar (Rochester), Vincent Rajkumar (Rochester)

11:00-11:05	Introduction	Shaji Kumar (Rochester) Vincent Rajkumar (Rochester)
11:05-11:20	MGUS	Vincent Rajkumar (Rochester)
11:20-11:25	*Discussion*	
11:25-11:40	AL Amyloidosis	Vaishali Sanchorawala (Boston)
11:40-11:45	*Discussion*	
11:45-12:00	Waldenstrom Macroglobulinemia	Prashant Kapoor (Rochester)
12:00-12:05	*Discussion*	
12:05-12:35	*Panel discussion*	

12:35-12:45 Closing remarks

MEETING CLOSURE